Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 ...
InvestorsHub on MSN

Arbutus shares jump after FDA grants fast track status to hepatitis B therapy

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares climbed 6% on Wednesday after the company revealed it had received Fast ...
Investing.com South Africa

Arbutus stock jumps 6% on FDA fast track designation

Arbutus Biopharma Corporation (NASDAQ:ABUS) shares rose 6% Wednesday after the company announced it received Fast Track designation from the U.S. Food and Drug Ad ...

Arbutus Biopharma Gets FDA Fast-Track Designation for Imdusiran in Chronic Hepatitis B

Arbutus Biopharma has won U.S. Food and Drug Administration fast-track designation for its proposed imdusiran treatment for chronic hepatitis B, a serious liver infection. The Warminster, Pa., ...

Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma

OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...
Targeted Oncology

FDA Grants Fast Track Designation to ADC for Platinum-Resistant Ovarian Cancer

Fast Track status enables closer FDA engagement to potentially accelerate development of a CDH6-directed ADC in ...
Morningstar

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

NASHVILLE, Tenn., Feb. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today ...
Targeted Oncology

FDA Grants Fast Track Designation to OPN-6602 for Multiple Myeloma

The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
Nasdaq

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
The Bakersfield Californian

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic ...

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ...